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males. There were 7 with adenocarcinoma, 3 squamous cell cancer, 1 
with large cell and 1 with poorly differentiated non small cell cancer. 
One of the 12 patients had assessable but no measurable disease. 
Eight patients (66%) achieved a partial response, one achieved a minor 
response, two had stable disease, and one had progressive disease in 
one site with tumor regression in all other sites. Median survival was 
16.5 months and 5 patients are still being followed. The number of 
cycles was 1-6, median of 3. There was 1 case of grade 4 thrombocy-
topenia without bleeding, 2 cases of line related sepsis; 2 patients with 
neutropenic infection, 2 patients with DVT (1 related to central line) 
and 1 of peripheral neuropathy related to Taxotere requiring discontinu-
ation; 1 patient had a bleeding peptic ulcer successfully treated. There 
was no evidence of skin rashes, headaches, unexplained leukocytosis or 
other ﬁndings suggestive of retinoic acid syndrome. There was no case 
of pancreatitis. No dose modiﬁcation of the retinoids was needed. 
The combination of brief periods of RAR and RXR agonists given 
together, along with chemotherapy appears to produce promising 
responses and survival in this group of patients. The brief period of 
administration of both agents may limit side effects reported with reti-
noids. This raises the hypothesis that the high response rate observed 
is due to increased anti-tumor activity through cross-talk and heterodi-
merization of the RAR and RXR receptors. A follow up trial has been 
initiated. 
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Response rates of erlotinib or gefitinib compared to docetaxel as 
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Background: In randomized trials, docetaxel has been shown to have 
activity as second-line therapy in advanced NSCLC; and erlotinib in 
the third-line setting after failure of ﬁrst-line platinum-based chemo-
therapy. The role of epidermal growth factor receptor tyrosine kinase 
inhibitors (EGFRTKI) as second-line treatment prior to docetaxel 
chemotherapy remains ill deﬁned and is currently the subject of several 
ongoing trials. Here we explore the outcomes of these agents’ uses in 
clinical practice. 
Method: A retrospective review of the NSCLC database at Princess 
Margaret Hospital in Toronto, Canada was undertaken. Patients who 
have previously received docetaxel after failure of platinum-based 
chemotherapy were identiﬁed and a chart review was undertaken to 
further identify those who also received erlotinib or geﬁtinib to assess 
the clinical beneﬁt of these drugs. The primary outcome assessed was 
response rate and secondary outcomes were time to progression and 
survival.
Results: 77 patients received docetaxel for advanced NSCLC from 
2001 to Dec 2006. Of these, 55 (71%) were administered as second-
line treatment following failure of platinum-based chemotherapy, 20 
(26%) received it in the third-line setting and two (3%) as fourth-line 
treatment (see Table 1). Assessable response rates to second line 
docetaxel were partial response (PR) of 4%, stable disease (SD) of 47% 
and progressive disease (PD) in 49%. Of these 55 patients, 26 subse-
quently went to receive an EGFRTKI. Assessable response rates in 
these patients to third-line EGFRTKI were CR in 4% (1/23), PR in 9% 
(2/23), SD in 26% (6/23) and PD in 61% (14/23). Three patients were 
not assessable for response due to death and withdrawal from medica-
tion prior to assessment.
In the 20 patients who received docetaxel in the third line setting, 17 
received prior EGFRTKI therapy. Response rates to an EGFRTKI in 
second line were PR of 12% (2/17), SD of 6% (1/17) and PD of 82% 
(14/17) while responses to third-line docetaxel were PR of 8% (1/13), 
SD of 69% (9/13) and PD of 23% (3/13). Seven were not assessable for 
response due to death or withdrawal prior to assessment.
Updated data on demographics and secondary outcomes will be pre-
sented at the meeting.
Conclusions: In this retrospective non-randomized review of patients 
with advanced NSCLC who progressed following ﬁrst-line platinum-
based chemotherapy, the use of an EGFRTKI as second-line therapy 
did not appear to be superior to when it is administered in the third-line 
setting following docetaxel chemotherapy. However, this may be con-
founded by selection bias. Randomized studies are required to directly 
test this hypothesis.
Table1. Response rates of EGFRTKI and docetaxel in 2nd and 3rd line setting
 CR PR SD PD
2nd line therapy 
EGFRTKI 0% 12% 6% 82%
Docetaxel 0% 4% 47% 49%
3rd line therapy
EGFRTKI 4% 9% 26% 61%
Docetaxel 0% 8% 69% 23%
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Background: Elderly patients with advanced non-small-cell lung 
cancer (NSCLC) are often unsuitable for platinum-based chemo-
therapy due to comorbidity. Monotherapy, for example docetaxel, is the 
preferred treatment for elderly patients (Kudoh. J Clin Oncol 2006). 
EGFR tyrosine kinase inhibitors, such as geﬁtinib and erlotinib, show 
remarkable responses in some patients with NSCLC. Adenocarcinoma 
histology and Asian origin are predictors of these responses. Therefore, 
we conducted a phase II study of geﬁtinib as a ﬁrst-line therapy in 
elderly patients with lung adenocarcinoma in Japan.
Methods: Eligible patients with stage IIIB/IV lung adenocarcinoma 
were 70 years or older, chemotherapy-naïve, and had a performance 
status of 2 or lower. Patients with interstitial pneumonitis that was 
detectable on a chest computed tomogram were ineligible. Eligible 
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patients were treated with geﬁtinib 250 mg/day orally until disease 
progression. The primary endpoint was response rate. The secondary 
endpoints were disease control rate, overall survival, progression-free 
survival, and toxicity.
Results: Thirty-one patients were enrolled in this study from December 
2004 to December 2005. One patient was ineligible because of IIIA 
disease. Of the 30 eligible patients, the median age was 78.5 years, 
16 patients were female, and 14 patients had no smoking history. We 
observed no CR, 7 PR, 8 SD, 13 PD, and 2 NE (unconﬁrmed extra-
murally). The response rate was 23% and the disease control rate was 
50%. The median overall survival was 11.9 months and the median 
progression-free survival was 3.2 months. In never-smokers, the 
response rate was 43%, the disease control rate was 57%, the median 
overall survival was 15.0 months, and the median progression-free 
survival was 7.1 months. The common grade 3 to 4 toxicities were 
rash (7%), diarrhea (3%), anorexia (7%), fatigue (3%), AST (7%), and 
ALT (7%). We encountered one acute myocardial infarction (grade 4) 
that was considered as therapy-unrelated. There was no interstitial lung 
disease and no treatment-related death.
Conclusions: Single-agent geﬁtinib is active and well tolerated in che-
motherapy-naïve elderly patients with lung adenocarcinoma. Geﬁtinib 
may become a new standard treatment characterized by less toxicity, 
especially in never-smokers. Further investigation is warranted in Asia.
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Percutaneous ethanol injection for treatment of cervical lymph 
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Objective: The objective of this study was to evaluate the technique, 
efﬁcacy, and side effects of percutaneous ethanol injection in patients 
with symptomatic cervical nodal metastases from lung cancer. 
Methods: twenty patients who had received previous chemotherapy 
or radiotherapy for advanced lung cancer presented with symptomatic 
nodal metastases in the neck between May 2006 and october 2006. all 
were unresponsive to chemotherapy and radiotherapy. each metastatic 
lymph node was treated with percutaneous ethanol injection, and pa-
tients received both clinical and sonographic follow-up. 
Results: thirty-ﬁve metastatic lymph nodes in our 20 patients were 
injected. mean sonographic follow-up was 1 months (range, from 0.5 
months to 4 months). Thirty treated lymph nodes(85.7%)decreased in 
mean diameter from 26.2mm before percutaneous ethanol injection to 
15.7mm at 1 month after treatment. the mean improvement in the pain 
score after alcohol injection was 2.5±1.2. nine nodes were re-treated 
1-2months after initial percutaneous ethanol injection because of recov-
ered ﬂow on color Doppler sonography (n = 4), or increased size (n = 
5). No major complications occurred.
Conclusion: Sonographically guided percutaneous ethanol injection 
is a valuable treatment option for patients with symptomatic cervical 
nodal metastases from advanced lung cancer who are not amenable to 
further therapy. 
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Background: Geﬁtinib, an epidermal growth factor receptor(EGFR) 
tyrosine kinase inhibitor, has reported to be effective in refractory non-
small cell lung carcinoma(NSCLC). In a subgroup analysis of ISEL 
trial, oriental and non-smokers had improvements in survival. This 
study aimed to ﬁnd the clinical and genetic parameters that predict the 
response and survival beneﬁt of geﬁtinib in a Korean population.
Methods: Since 2002, 187 patients with NSCLC were treated with 
geﬁtinib and their response evaluations were feasible. The responses 
were recorded as partial remission(PR), stable disease(SD) and 
progression(PD) by RECIST response criteria for solid tumor. Sev-
enty-one tumor DNA were available for the sequence analysis of the 
EGFR gene(exon 18, 19, 20, and 21), 60 tumor DNA were examined 
for K-ras(codon 12, and 61) and 45 for HER-2 gene(exon 19 and 20) 
mutation.
Results: The response rate was signiﬁcantly higher in those who 
never smoked(47.9%) vs. smokers(10.8%, p<0.001), in females(40%) 
vs. males(13.1%, p<0.001), in adenocarcinoma(33%) vs. non-
adenocarcinoma(7.5%, p<0.001) and in EGFR mutants(88.2%) 
vs. wild type(14.8%, p<0.001). By a multivariate logistic regres-
sion analysis, the independent clinical predictors of response were 
adenocarcinoma(OR=0.245, 95% CI, 0.096-0.629, p=0.003) and never 
smokers(OR=0.126, 95% CI, 0.032-0.504, p=0.003). Among patients 
whose EGFR gene sequence was examined, the only independent 
predictor of response was mutation fo EGFR gene(OR=0.038, 95% 
CI, 0.006-0.240, p=0.001). The median survival time from the begin-
ning of treatment with geﬁtinib was 7.7 months(95% CI, 6.25-9.15). 
Median survival was signiﬁcantly longer in responders(29.8 months, 
p<0.001), never smoked patients(26.7 months, p<0.001), females(12.4 
months, p=0.002), adenocarcinoma(9.4 months, p=0.009) and EGFR 
mutants(not reached, p<0.001). The independent clinical predictors of 
the survival were female(OR=2.041, 95% CI, 1.081-3.855, p=0.028) 
and never smokers(OR=0.170, 95% CI, 0.082-0.351, p=0.000). 
In patients whose EGFR gene sequence were analysed, EGFR 
mutation(OR=0.368, 95% CI, 0.145-0.934, p=0.035) and never smok-
ing history(OR=0.177, 95% CI, 0.067-0.465, p=0.000) were indepen-
dent predictors of survival. 
Conclusions: The patients who respondrd to geﬁtinib showed signiﬁ-
cantly longer survival than non-responders. The independent predictors 
of response and survival were never smoking history, adenocarcinoma, 
and female sex. Among patients whose EGFR gene sequence were ana-
lyzed, EGFR gene mutation was the independent predictor of response 
and survival. 
